The CVR creates a potential catalyst path tied to rare pediatric disease voucher monetization, but with no approved product or awarded voucher, this is a long-dated, binary event. Monitor (Z)-endoxifen clinical and regulatory progress for any signal of voucher eligibility.
Price Chart
Executive Summary
Atossa Therapeutics announced a plan to issue one contingent value right (CVR) per share of common stock, entitling holders to 25% of net proceeds from monetization of the company's first qualifying rare pediatric disease priority review voucher, capped at $50 million aggregate. No product candidate has been approved and no voucher has been awarded to date, so any CVR payment is highly uncertain and contingent on future regulatory milestones.
Key Facts
- Board approved plan to issue one CVR per share of common stock
- CVR holders entitled to 25% of net proceeds from monetization of first qualifying rare pediatric disease priority review voucher
- Aggregate payment capped at $50 million
- No product candidate has been approved and no voucher has been awarded to date
- CVRs expire December 31, 2036 if no qualifying voucher awarded
- CVRs are stapled to shares and do not trade separately
- Atossa has received two FDA rare pediatric disease designations for (Z)-endoxifen (Duchenne muscular dystrophy and McCune-Albright syndrome)
Financial Impact
Potential CVR payment of up to $50 million aggregate (25% of net voucher proceeds), but no voucher has been awarded and no payment is assured
Risk Factors
- No product candidate has been approved and no voucher has been awarded to date
- CVR payment is entirely contingent on future FDA approval and voucher award
- Voucher program rules could change or expire before any award
- CVR cap of $50 million limits upside even if voucher value is higher
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-406036 |
| Document: atos-ex99_1.htm | 0001193125-26-406036 |
| Document: 0001193125-26-406036-index-headers.html | 0001193125-26-406036 |
| Document: 0001193125-26-406036-index.html | 0001193125-26-406036 |
| Document: 0001193125-26-406036.txt | 0001193125-26-406036 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 8-K | $2.44 | awaiting T+60 | — | $2.45 (+0.41%) |
Sep 29, 2026 27d ago | 8-K | $1.99 | awaiting T+60 | — | $2.45 (+23.12%) |
Sep 18, 2026 5w ago | 8-K | $2.25 | awaiting T+60 | — | $2.45 (+8.89%) |
Aug 7, 2026 11w ago | 8-K | $2.36 | awaiting T+60 | — | $2.45 (+3.81%) |
Aug 7, 2026 11w ago | Press Release | $2.36 | awaiting T+60 | — | $2.45 (+3.81%) |
Jun 12, 2026 19w ago | 424B5 | $2.46 $2.52 | ▼ −2.24% | ▲ +1.03% | $2.45 (+0.41%) |
Apr 16, 2026 27w ago | 8-K | $5.77 $2.40 | ▼ −58.41% | ▼ −65.45% | $2.45 (−57.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers